Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
Status:
Completed
Trial end date:
2014-09-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability and describe the maximum
tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with
bevacizumab and paclitaxel for patients with advanced solid tumors.